Advertisement

Angiographic endpoints in progression trials

  • A. V. G. Bruschke
  • J. W. Jukema
  • A. J. Van Boven
  • E. T. Bal
  • J. H. C. Reiber
  • A. H. Zwinderman
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 180)

Summary

The use of different angiographic criteria represents one of the reasons why the results of angiographic trials are difficult to compare. In principle, this is an avoidable problem and therefore a serious attempt at standardization should be made. This chapter reviews the criteria which have been used in trials using quantitative coronary angiography and presents a proposal for standardization.

Keywords

Coronary Atherosclerosis Quantitative Coronary Angiography Angiographic Data Focal Change Progression Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med. 1993;119:969–76.PubMedGoogle Scholar
  2. 2.
    Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–98.PubMedCrossRefGoogle Scholar
  3. 3.
    Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975–90.PubMedGoogle Scholar
  4. 4.
    Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Pitt B, Mancini GB, Ellis SG, Rosman HS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I) [abstract]. J Am Coll Cardiol. 1994;23 Special issue: 131A.Google Scholar
  6. 6.
    The MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) [published erratum appears in Lancet. 1994;344:762]. Lancet. 1994;344:633–8.CrossRefGoogle Scholar
  7. 7.
    Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959–68.PubMedGoogle Scholar
  8. 8.
    Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group. Lancet. 1994;344:1182–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Schuler G, Hambrecht R, Schlierf G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation. 1992;86:1–11.PubMedGoogle Scholar
  10. 10.
    Watts GF, Lewis B, Brunt JN, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528–40.PubMedGoogle Scholar
  12. 12.
    Quinn TG, Alderman EL, McMillan A, Haskell W. Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). J Am Coll Cardiol. 1994;24:900–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Bruschke AV, Padmos I, Buis B, Van Benthem A. Arteriographic evaluation of small coronary arteries. J Am Coll Cardiol. 1990;15:784–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Reiber JH, Jukema W, van Boven A, van Houdt RM, Lie KI, Bruschke AV. Catheter sizes for quantitative coronary arteriography. Cathet Cardiovasc Diagn. 1994;33:153–5; discussion 156.PubMedCrossRefGoogle Scholar
  15. 15.
    Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530–8.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • A. V. G. Bruschke
  • J. W. Jukema
  • A. J. Van Boven
  • E. T. Bal
  • J. H. C. Reiber
  • A. H. Zwinderman

There are no affiliations available

Personalised recommendations